NCT00044681View on ClinicalTrials.gov

A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression

PHASE3CompletedINTERVENTIONAL

Enrollment

258

Participants

Timeline

Start Date

October 31, 2002

Study Completion Date

March 31, 2004

Conditions

Depressive DisorderDepressive Disorder, MajorDepression

Interventions

DRUG

risperidone

All Listed Sponsors

collaborator

Janssen, LP

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00044681 - A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression | Biotech Hunter | Biotech Hunter